Home › Biliary Tract Cancer › Massachusetts
Biliary Tract Cancer clinical trials in Massachusetts
11 studies for Biliary Tract Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 16 and older · All sexes · Updated Nov 12, 2026 · NCT07197554A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07458347A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07020221A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06760819AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Boston
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Oct 16, 2026 · NCT07038343Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06239194Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 8 and older · All sexes · Updated Jul 27, 2026 · NCT05503797This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 2, 2026 · NCT06451497Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Mass General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 5, 2026 · NCT04900818From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.